About Arch Pharmalabs
Arch Pharmalabs is a company based in Mumbai (India) founded in 1999 was acquired by Neuland in December 2017. Arch Pharmalabs has raised $68 million across 1 funding round from investors including Mitsui & Co and Neuland Labs. The company has 412 employees as of April 08, 2024. Arch Pharmalabs offers products and services including APIs, Intermediates, and Contract Services. Arch Pharmalabs operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Mumbai, India
- Employees 412 as on 08 Apr, 2024
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arch Pharmalabs Limited
- Date of Incorporation 02 Apr, 1993
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$161.62 M (USD)2.29as on Mar 31, 2023
-
Net Profit
$14.68 M (USD)135.44as on Mar 31, 2023
-
EBITDA
$21.6 M (USD)1.62as on Mar 31, 2023
-
Total Equity Funding
$68 M (USD)
in 1 rounds
-
Latest Funding Round
$68 M (USD), Series C
Jan 17, 2013
-
Investors
Mitsui & Co.
& 1 more
-
Employee Count
412
as on Apr 08, 2024
-
Acquired by
Neuland
(Dec 13, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Arch Pharmalabs
Arch Pharmalabs offers a comprehensive portfolio of products and services, including APIs, Intermediates, and Contract Services.
Production of active pharmaceutical ingredients for drug development
Manufacture of chemical intermediates used in pharmaceuticals
Provision of contract research and manufacturing for partners
People of Arch Pharmalabs
Unlock access to complete
Funding Insights of Arch Pharmalabs
Arch Pharmalabs has successfully raised a total of $68M through 1 strategic funding round. The most recent funding activity was a Series C round of $68 million completed in January 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $68.0M
-
First Round
First Round
(17 Jan 2013)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2013 | Amount | Series C - Arch Pharmalabs | Valuation | Mitsui |
|
Investors in Arch Pharmalabs
Arch Pharmalabs has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Mitsui & Co and Neuland Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional conglomerate services are provided across multiple sectors by Mitsui.
|
Founded Year | Domain | Location | |
|
Active pharmaceutical ingredients and peptides are manufactured globally.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arch Pharmalabs
Financial Statements - Arch Pharmalabs
Arch Pharmalabs Comparisons
Competitors of Arch Pharmalabs
Arch Pharmalabs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical and biotechnology company
|
|
| domain | founded_year | HQ Location |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| domain | founded_year | HQ Location |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
APIs, intermediates, and biochemical reagents are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
APIs are developed and manufactured for therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Contract development, manufacturing, and analytical services for APIs are offered.
|
Frequently Asked Questions about Arch Pharmalabs
Arch Pharmalabs was founded in 1999 and raised its 1st funding round 14 years after it was founded.
Arch Pharmalabs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Arch Pharmalabs is a funded company, having raised a total of $68M across 1 funding round to date. The company's 1st funding round was a Series C of $68M, raised on Jan 17, 2013.
As of Apr 08, 2024, the latest employee count at Arch Pharmalabs is 412.
Annual revenue of Arch Pharmalabs is $161.62M as on Mar 31, 2023.
Arch Pharmalabs, is a provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates and manufacture for the global pharmaceutical industry. In Sep2010 Japanese conglomerate Mitsui has bought a 5 stake in Arch Pharmalabs, for around INR 65 crore and additional 25 in Sept2012 for INR 372 Crore. Mitsui bought out the stakes of ILFS Trust Co, IDBI Trusteeship Services Rainbow Fund, ICICI ventures.
Arch Pharmalabs's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
Arch Pharmalabs offers APIs, Intermediates, and Contract Services.
Arch Pharmalabs has 2 investors. Key investors include Mitsui & Co, and Neuland Labs.